CCEL — Cryo-Cell International Cashflow Statement
0.000.00%
Last trade - 00:00- $36.68m
- $40.67m
- $31.99m
- 79
- 97
- 68
- 96
Annual cashflow statement for Cryo-Cell International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3.62 | 2.08 | 2.77 | -9.52 | 0.402 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2 | 1.59 | 1.78 | 17.8 | 1.53 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.76 | 4.86 | 4.25 | 5.99 | 3.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 8.47 | 7.93 | 8.57 | 8.92 | 6.01 |
| Capital Expenditures | -0.1 | -1.84 | -12.2 | -6.84 | -2.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.457 | -5.11 | -3.11 | -1.31 | -2.47 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.357 | -6.95 | -15.3 | -8.14 | -4.88 |
| Financing Cash Flow Items | -0.045 | 0 | -0.197 | -0.068 | 0.228 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5 | -3.07 | 0.148 | -2.07 | -0.979 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.82 | -2.1 | -6.56 | -1.3 | 0.155 |